Mitchell S Fourman1, Duncan C Ramsey1, Erik T Newman1, Joseph H Schwab2, Yen-Lin Chen3, Yin P Hung4, Ivan Chebib4, Vikram Deshpande4, G Petur Nielsen4, Thomas F DeLaney3, John T Mullen5, Kevin A Raskin1, Santiago A Lozano Calderón6. 1. Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA. 2. Spine Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA. 3. Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. 4. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. 5. Surgical Oncology Service, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. 6. Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA. slozanocalderon@mgh.harvard.edu.
Abstract
BACKGROUND: Local recurrence of microinvasive sarcoma or benign aggressive pathologies can be limb- and life-threatening. Although frozen pathology is reliable, tumor microinvasion can be subtle or missed, having an impact on surgical margins and postoperative radiation planning. The authors' service has begun to temporize the tumor bed after primary tumor excision with a wound vacuum-assisted closure (VAC) pending formal margin analysis, with coverage performed in the setting of final negative margins. METHODS: This retrospective analysis included all patients managed at a tertiary referral cancer center with VAC temporization after soft tissue sarcoma or benign aggressive tumor excision from 1 January 2000 to 1 January 2019 and at least 2 years of oncologic follow-up evaluation. The primary outcome was local recurrence. The secondary outcomes were distant recurrence, unplanned return to the operating room for wound/infectious indications, thromboembolic events, and tumor-related deaths. RESULTS: For 62 patients, VAC temporization was performed. The mean age of the patients was 62.2 ± 22.3 years (median 66.5 years; 95% confidence interval [CI] 61.7-72.5 years), and the mean age-adjusted Charlson Comorbidity Index was 5.3 ± 1.9. The most common tumor histology was myxofibrosarcoma (51.6%, 32/62). The mean volume was 124.8 ± 324.1 cm3, and 35.5% (22/62) of the cases were subfascial. Local recurrences occurred for 8.1% (5/62) of the patients. Three of these five patients had planned positive margins, and 17.7% (11/62) of the patients had an unplanned return to the operating room. No demographic or tumor factors were associated with unplanned surgery. CONCLUSIONS: The findings showed that VAC-temporized management of microinvasive sarcoma and benign aggressive pathologies yields favorable local recurrence and unplanned operating room rates suggestive of oncologic and technical safety. These findings will need validation in a future randomized controlled trial.
BACKGROUND: Local recurrence of microinvasive sarcoma or benign aggressive pathologies can be limb- and life-threatening. Although frozen pathology is reliable, tumor microinvasion can be subtle or missed, having an impact on surgical margins and postoperative radiation planning. The authors' service has begun to temporize the tumor bed after primary tumor excision with a wound vacuum-assisted closure (VAC) pending formal margin analysis, with coverage performed in the setting of final negative margins. METHODS: This retrospective analysis included all patients managed at a tertiary referral cancer center with VAC temporization after soft tissue sarcoma or benign aggressive tumor excision from 1 January 2000 to 1 January 2019 and at least 2 years of oncologic follow-up evaluation. The primary outcome was local recurrence. The secondary outcomes were distant recurrence, unplanned return to the operating room for wound/infectious indications, thromboembolic events, and tumor-related deaths. RESULTS: For 62 patients, VAC temporization was performed. The mean age of the patients was 62.2 ± 22.3 years (median 66.5 years; 95% confidence interval [CI] 61.7-72.5 years), and the mean age-adjusted Charlson Comorbidity Index was 5.3 ± 1.9. The most common tumor histology was myxofibrosarcoma (51.6%, 32/62). The mean volume was 124.8 ± 324.1 cm3, and 35.5% (22/62) of the cases were subfascial. Local recurrences occurred for 8.1% (5/62) of the patients. Three of these five patients had planned positive margins, and 17.7% (11/62) of the patients had an unplanned return to the operating room. No demographic or tumor factors were associated with unplanned surgery. CONCLUSIONS: The findings showed that VAC-temporized management of microinvasive sarcoma and benign aggressive pathologies yields favorable local recurrence and unplanned operating room rates suggestive of oncologic and technical safety. These findings will need validation in a future randomized controlled trial.
Authors: Kristo Nuutila; Antti Siltanen; Matti Peura; Ari Harjula; Tapio Nieminen; Jyrki Vuola; Esko Kankuri; Pertti Aarnio Journal: Burns Date: 2012-11-08 Impact factor: 2.744
Authors: Daniel Winchester; Julia Lehman; Tiffany Tello; Nicolette Chimato; Thomas Hocker; Sunhee Kim; Joseph Chang; Jeffrey Markey; Sue S Yom; William Ryan; Thaddeus Mully; David Hodge; Clark Otley; Sarah T Arron Journal: J Am Acad Dermatol Date: 2018-05-19 Impact factor: 11.527
Authors: Paolo Erba; Rei Ogawa; Maximilian Ackermann; Avner Adini; Lino F Miele; Pouya Dastouri; Doug Helm; Steven J Mentzer; Robert J D'Amato; George F Murphy; Moritz A Konerding; Dennis P Orgill Journal: Ann Surg Date: 2011-02 Impact factor: 12.969
Authors: Alex Senchenkov; Paul M Petty; James Knoetgen; Steven L Moran; Craig H Johnson; Ricky P Clay Journal: World J Surg Oncol Date: 2007-11-29 Impact factor: 2.754